Back to All Combinations

BRAF Non-V600

Intermediate Prognosis
2.00% Prevalence Level 3 BRAF Pathway
Genes Involved
BRAF
Treatment Implications

Different biology. May retain anti-EGFR sensitivity.

Recommended Treatments
Standard chemotherapy
Anti-EGFR possible
Treatments to Avoid
Encorafenib
Study References

Yaeger et al

Key Statistics
2.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Class 2/3 mutations behave differently.
Information

Category: BRAF Pathway

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.